Bronchodilator medicines - Clinical trials 

  • Clinical trials

Clinical trials for Bronchodilator medicines

Information provided by WHO International Clinical Trials Registry

The clinical trials below are relevant to Bronchodilator medicines. For all clinical trials, go to clinical trials search

This list shows clinical trials for Bronchodilator medicines

Search result filters
Recruitment status
Trials for children:
Country of trial:

You have searched for the following terms

  • Bronchodilator medicines
Title Recruitment status Location
Determining the optimal approach to identifying individuals with chronic obstructive pulmonary disease Recruiting United Kingdom
A comparison of devices for measurement of spirometry in normal healthy subjects and patients with respiratory disease Recruiting United Kingdom
Omalizumab in non atopic asthma Recruiting United Kingdom
Assessment of Ventilation-Perfusion Abnormalities in Patients With Stable Smoking-Related Airways Disease Recruiting United Kingdom
Inhaled Corticosteroid Withdrawal in Patients With Chronic Obstructive Pulmonary Disease Recruiting United Kingdom
A double-blind, placebo-controlled efficacy (as assessed by post-bronchodilator FEV1) and safety study of 5 mg RO3300074 once-daily for 2 years in subjects with smoking-related, moderate-to-severe COPD with emphysema receiving concurrent optimal COPD drug therapy. Not Recruiting United Kingdom
A double-blind, placebo-controlled efficacy (as assessed by post-bronchodilator FEV1) and safety study of 5 mg RO3300074 once-daily for 2 years in subjects with smoking-related, moderate-to-severe COPD with emphysema receiving concurrent optimal COPD drug therapy. Not Recruiting United Kingdom
The Bronchodilator Effect of Ultrafine Particles of Salbutamol Not recruiting United Kingdom
Biomarkers to target antibiotics and steroid therapy in chronic obstructive pulmonary disease (COPD) exacerbations Not recruiting United Kingdom
A double-blind, placebo-controlled efficacy (as assessed by post-bronchodilator FEV1) and safety study of 5 mg RO3300074 once-daily for 2 years in subjects with smoking-related, moderate-to-severe COPD with emphysema receiving concurrent optimal COPD drug therapy. Not Recruiting United Kingdom
  • Link to Directgov – public services all in one place
  • The Information Standard - Certified member